Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 17/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | NEK2 | P51955 | 1/20 | 0.46 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18980089 | 0.92 | KDM4E (0.53) | NOTUMKDM4ECYP2C19NEK2 | |
| SCHEMBL18980404 | 0.82 | KDM4E (0.46) | KDM4ECYP2C19NEK2 | |
| SCHEMBL15775592 | 0.76 | KDM4E (0.48) | NOTUMKDM4ECYP2C19NEK2 | |
| SCHEMBL20670365 | 0.75 | TP53 (0.47) | KDM4E | |
| SCHEMBL30595450 | 0.75 | TP53 (0.47) | KDM4E | |
| SCHEMBL10078646 | 0.74 | CYP8B1 (0.53) | NOTUMCYP2C19KEAP1 | |
| SCHEMBL1224565 | 0.74 | CYP8B1 (0.53) | NOTUMCYP2C19KEAP1 | |
| SCHEMBL3665484 | 0.74 | CYP8B1 (0.53) | NOTUMCYP2C19KEAP1 | |
| SCHEMBL23879296 | 0.73 | CTSB (0.36) | KDM4E | |
| SCHEMBL15618990 | 0.73 | PBK (0.50) | NOTUMKDM4ECYP2C19KEAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110944990-B | TLR7/8 antagonists and uses thereof | 默克专利股份公司 | 2024-06-18 | — | — | CN | disclosed |
| EP-4248968-A2 | TLR7/8 ANTAGONISTS AND USES THEREOF | Merck Patent GmbH (DE) | 2023-09-27 | — | — | EP | disclosed |
| US-20200369648-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2020-11-26 | — | — | US | disclosed |
| US-10836750-B1 | TLR7/8 antagonists and uses thereof | MERCK PATENT GMBH (DE) | 2020-11-17 | — | — | US | disclosed |
| US-10793553-B2 | TLR7/8 antagonists and uses thereof | MERCK PATENT GMBH (DE) | 2020-10-06 | — | — | US | disclosed |
| EP-3655401-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | Merck Patent GmbH (DE) | 2020-05-27 | — | — | EP | disclosed |
| CN-110944990-A | TLR7/8 antagonists and uses thereof | 默克专利股份公司 | 2020-03-31 | — | — | CN | disclosed |
| WO-2019018354-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2019-01-24 | — | — | WO | disclosed |
| US-20190023687-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2019-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200369648-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | TLR7, TLR8, TLR9 | NOTUM 4327/4885KDM4E 2161/4885CYP2C19 3047/4885 |
| US-20190023687-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | TLR7, TLR8, TLR9 | NOTUM 4256/4885KDM4E 1982/4885CYP2C19 2398/4885 |
| US-10793553-B2 | TLR7/8 antagonists and uses thereof | TLR7, TLR8, TLR9 | NOTUM 4256/4885KDM4E 1982/4885CYP2C19 2398/4885 |
| US-10836750-B1 | TLR7/8 antagonists and uses thereof | TLR7, TLR8, TLR9 | NOTUM 4327/4885KDM4E 2161/4885CYP2C19 3047/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.